Skip to main content
Log in

High or low dose radioiodine ablation of thyroid remnants?

  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

The need for high dose radioiodine for ablation of remnants in patients with thyroid cancer is still in question. We compared the effectiveness of high and low dose131I for ablation in patients in a prospective randomized study after surgical thyroidectomy. Twenty patients with differentiatedpT2-3NoMo thyroid cancer were studied. The uptake was 5%–10% at 24 h. Ten patients received 100 mCi, the others 30 mCi131I. Three months later all patients received a therapeutic dose of 150 mCi131I. Another twenty patients with known distant metastases (pulmonary and/or bone) of differentiated thyroid cancer were studied. The remnant uptake was between 4%–10%. Ten patients received 300 mCi and ten 30 mCi131I as ablation dose. Three months later all received 300 mCi131I. The uptake at day seven was calculated for the same metastases from a whole body scan after both treatments. If effective ablation was defined as 24h uptake in the remnant of less than 1%, then the ablation was effective in eight out of ten of the high dose and in seven out of ten of the low dose group. In pT2-3, NxM1 patients the ablation was effective in seven out of ten cases in both groups. If “effective” ablation was defined as an uptake of less than 0.5%, then the ablation was effective both in NoMo and in NxM1 patients in five out of ten with low dose and in six out of ten with high dose ablation treatment. Seventh day uptake in 20 metastases after the second dose was at mean 3.6 times (range 2.8–4.3) higher than after the first, while there was no significant difference in TSH levels. In two patients,131I kinetics over a bone metastasis were recorded continuously during 300 mCi ablation treatment and 300 mCi therapeutic treatment without any significant difference. We therefore recommend a 30 mCi ablation dose for all patients with differentiated thyroid cancer after surgical thyroidectomy, followed by a 300 mCi treatment dose in pT2-3N1M x or pT2-3N x M1 patients, while in pT2-3NoMo low dose ablation will be a sufficient treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Beierwaltes WH, Rabbani R, Dmuchowski C (1984) An analysis of “Ablation of thyroid remnants” with I-131 in 511 patients from 1947–1984. J Nucl Med 25:1287–1293

    Google Scholar 

  • DeGroot LJ, Reilly M (1982) Comparision of 30 and 50 mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 23:483–489

    Google Scholar 

  • Freitas J, Gross MD, Ripley S (1985) Radionuclide diagnosis and therapy of thyroid cancer: Current status report. Semin Nucl Med 15:106–131

    Google Scholar 

  • Günther M (1986) Strahlenexposition bei hochdosierter Radiojod-therapie. Dissertation Medizinische Hochschule Hannover

  • Hundeshagen H (1983) Postoperative diagnosis and therapy of thyroid carcinoma by nuclear medicine. Eur J Nucl Med 8:541–545

    Google Scholar 

  • Hurley RJ, Becker (1983) DV The use of radioiodine in the management of thyroid cancer. In: Freeman LM, Weissmann HS (eds) Nuclear Medicine Annual (1983). Raven Press, New York, pp 173–182

    Google Scholar 

  • Kuni CC, Klingensmith WC III (1980) Failure of low doses of I-131 to ablate residual thyroid tissue following surgery for thyroid cancer. Radiology 137:73–774

    Google Scholar 

  • Leisner B, Degelmann G, Dirr W (1982) Behandlungsergebnisse bei Struma Maligna 1960–1980. Dtsch Med 107:1702–1707

    Google Scholar 

  • Maxon HR, Thomas SR, Hertzberg VS (1983) Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937–944

    Google Scholar 

  • McCowan KD, Adler RA, Ghaed N Low-dose radioiodine thyroid ablation in postsurgical patients with thyroid cancer. Am J Med 61:52–58

  • Pretschner P Emgymetrie (1982) Springer Verlag, Heidelberg, Berlin, New York

  • Schümichen C, Schmitt E (1982) Schilddrüsenkarzinom — Behandlungsergebnisse in Freiburg. In: Biersack HJ, Winkler C, Baysel D (eds) Neue Aspekte in Diagnose und Therapie des Schilddrüsenkarzinoms. Schattauer, Stuttgart, pp 193–202

    Google Scholar 

  • Siddiqui AR, Edmondson J, Wellmann HN (1981) Feasibility of low doses of I-131 for thyroid ablation in postsurgical patients with thyroid carcinoma. Clin Nucl Med 6:158–161

    Google Scholar 

  • Snyder J, Gorman C, Scanion P (1983) Thyroid remnant ablation: questionable pursuit of an ill-defined goal. J Nucl Med 24:659–665

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported in part by Deutsche Forschungsgemeinschaft (grant Cr 52/4-1)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Creutzig, H. High or low dose radioiodine ablation of thyroid remnants?. Eur J Nucl Med 12, 500–502 (1987). https://doi.org/10.1007/BF00620474

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00620474

Key words

Navigation